Evidence map›Paper›PMID 27457718›Full record

ArticleJournal of bacteriology2016

Mutagen Synergy: Hypermutability Generated by Specific Pairs of Base Analogs.

Jocelyn Ang, Lisa Yun Song, Sara D'Souza, Irene L Hong, Rohan Luhar, Madeline Yung, Jeffrey H Miller

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bacteriology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Recent progress in adaptive laboratory evolution of industrial microorganisms.Journal of industrial microbiology & biotechnology · 2023
    Article
  5. Review
  6. Article
  7. Recombineering and MAGE.Nature reviews. Methods primers · 2021
    Article
  8. Article
  9. Article
  10. Mutational Consequences of Ciprofloxacin in Escherichia coli.Antimicrobial agents and chemotherapy · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jocelyn AngDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Lisa Yun SongDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Sara D'SouzaDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Irene L HongDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Rohan LuharDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Madeline YungDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Jeffrey H MillerDepartment of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA jhmiller@microbio.ucla.edu.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledWe tested pairwise combinations of classical base analog mutagens in Escherichia coli to study possible mutagen synergies. We examined the cytidine analogs zebularine (ZEB) and 5-azacytidine (5AZ), the adenine analog 2-aminopurine (2AP), and the uridine/thymidine analog 5-bromodeoxyuridine (5BrdU). We detected a striking synergy with the 2AP plus ZEB combination, resulting in hypermutability, a 35-fold increase in mutation frequency (to 53,000 × 10(-8)) in the rpoB gene over that with either mutagen alone. A weak synergy was also detected with 2AP plus 5AZ and with 5BrdU plus ZEB. The pairing of 2AP and 5BrdU resulted in suppression, lowering the mutation frequency of 5BrdU alone by 6.5-fold. Sequencing the mutations from the 2AP plus ZEB combination showed the predominance of two new hot spots for A·T→G·C transitions that are not well represented in either single mutagen spectrum, and one of which is not found even in the spectrum of a mismatch repair-deficient strain. The strong synergy between 2AP and ZEB could be explained by changes in the dinucleoside triphosphate (dNTP) pools. IMPORTANCE: Although mutagens have been widely studied, the mutagenic effects of combinations of mutagens have not been fully researched. Here, we show that certain pairwise combinations of base analog mutagens display synergy or suppression. In particular, the combination of 2-aminopurine and zebularine, analogs of adenine and cytidine, respectively, shows a 35-fold increased mutation frequency compared with that of either mutagen alone. Understanding the mechanism of synergy can lead to increased understanding of mutagenic processes. As combinations of base analogs are used in certain chemotherapy regimens, including those involving ZEB and 5AZ, these results indicate that testing the mutagenicity of all drug combinations is prudent.

Indexed as

AzacitidineBase PairingBromodeoxyuridineCytidineDrug SynergismEscherichia coliEscherichia coli ProteinsMutagensMutationAzacitidineBromodeoxyuridineCytidineEscherichia coli ProteinsMutagenspyrimidin-2-one beta-ribofuranoside

Identifiers

PMID27457718
PMCPMC5038009
OpenAlexW2485890620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.